BC Extra | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

Karuna added about $1.8 billion in market cap Monday after a Phase II trial showed its combo therapy targeting muscarinic receptors led to significantly lower psychosis scores in patients with schizophrenia while avoiding the side...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Targeting muscarinic acetylcholine receptors to treat anemia

DISEASE CATEGORY: Hematology INDICATION: Anemia Muscarinic acetylcholine receptor antagonists could treat anemia associated with myelodysplastic syndrome (MDS), aging or hemolysis. In mice with MDS, a CHRM4 inhibitor tool compound, a CHRM1 inhibitor tool compound or...
BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BC Extra | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
BioCentury | Oct 26, 2018
Finance

Springing into Cerevel

Bain Capital is following the blueprint for Pfizer Inc. (NYSE:PFE) spinout SpringWorks Therapeutics LLC and applying it on a larger scale to Cerevel Therapeutics LLC, which will develop Pfizer’s discontinued neuroscience pipeline with $350 million...
BioCentury | Aug 3, 2018
Finance

Karuna’s CNS double play

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies. Along...
BC Week In Review | Aug 3, 2018
Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
BC Extra | Aug 2, 2018
Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
BC Innovations | Aug 1, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three...
BC Innovations | Jul 31, 2018
Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
Items per page:
1 - 10 of 23